KSA Diabetes Market Outlook to 2028

KSA Diabetes Market Overview

The diabetes market in the Kingdom of Saudi Arabia (KSA) is valued at USD 361 million, driven by the rising prevalence of diabetes, increasing healthcare expenditure, and government initiatives. According to data from the Saudi Ministry of Health and the International Diabetes Federation (IDF), diabetes affects 20% of the adult population in KSA. Factors contributing to the high incidence include poor dietary habits, sedentary lifestyles, and an aging population.

Dominant cities in the KSA diabetes market include Riyadh, Jeddah, and Dammam, primarily due to their advanced healthcare infrastructure and higher prevalence of diabetes cases. Riyadh and Jeddah have the highest concentration of healthcare facilities, specialists, and medical research centers, making them pivotal in diabetes treatment and management. Additionally, the population density and urbanization in these cities drive healthcare demand, particularly in terms of diabetes care. Furthermore, these cities have a more affluent population, which leads to increased adoption of advanced treatment methods and technologies.

Under Saudi Arabia's Vision 2030, the National Transformation Program (NTP) includes several key healthcare reforms designed to improve diabetes care, among other chronic diseases. These regulations focus on expanding the healthcare system, improving patient outcomes, and encouraging private sector participation in healthcare delivery.

KSA Diabetes Market Segmentation

By Product Type: The market is segmented by product type into insulin delivery devices, oral anti-diabetic drugs, continuous glucose monitoring (CGM) devices, and diabetes management software. Recently, insulin delivery devices have held a dominant market share due to their widespread use among Type 1 and advanced Type 2 diabetes patients. This sub-segment is driven by advancements in insulin pens and pumps, which offer more precise and convenient dosing options. With companies like Novo Nordisk and Eli Lilly providing state-of-the-art insulin delivery systems, their integration into daily patient care has grown. Moreover, the Saudi governments focus on modernizing healthcare has increased access to these devices, especially in major urban centers.

By Treatment Type: The market is also segmented by treatment type into pharmacological treatments (including insulin therapy, oral anti-diabetics) and non-pharmacological treatments (such as dietary interventions, exercise plans, and behavioral support). Among these, pharmacological treatments have dominated the market due to the growing reliance on insulin and oral medications to control blood glucose levels. Oral anti-diabetic drugs, particularly metformin and sulfonylureas, remain the first-line treatment for Type 2 diabetes. Meanwhile, insulin therapies are critical for patients with Type 1 diabetes and those with advanced Type 2 diabetes. The demand for pharmacological solutions has been supported by government subsidies and insurance coverage, making these treatments accessible to a broader patient base.

KSA Diabetes Market Competitive Landscape

The KSA diabetes market is characterized by the presence of global pharmaceutical giants as well as prominent regional players. Leading companies focus on innovative product development, strategic collaborations, and partnerships with healthcare providers to expand their market share. The competition is influenced by both pricing strategies and the ability to offer a comprehensive diabetes management solution, including medication, monitoring devices, and digital health platforms.

Major players include Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, and Medtronic, all of which have established themselves as leaders in diabetes care through their extensive product portfolios and research and development activities.

Competitive Landscape Table:

Company Name

Establishment Year

Headquarters

Revenue

R&D Expenditure

Product Portfolio

Novo Nordisk

1923

Denmark

Sanofi

1973

France

Eli Lilly

1876

USA

AstraZeneca

1999

UK

Medtronic

1949

USA

KSA Diabetes Industry Analysis

Growth Drivers

Increasing Prevalence of Type 2 Diabetes: Saudi Arabia has one of the highest diabetes prevalence rates globally. According to the International Diabetes Federation (IDF), 18.3% of the adult population (ages 2079) in Saudi Arabia lived with diabetes as of 2021. This is primarily attributed to rapid urbanization, sedentary lifestyles, and dietary changes, making Type 2 diabetes more widespread.

Rising Obesity and Lifestyle Changes: Obesity is a critical driver of the increasing diabetes burden in Saudi Arabia. As of 2021, over 35% of the Saudi population was classified as obese, driven by high-calorie diets, a lack of physical activity, and increasing fast-food consumption. Obesity is a significant risk factor for Type 2 diabetes, further exacerbating the growing prevalence of the disease.

Government Healthcare Reforms and Vision 2030: Saudi Arabia's Vision 2030 focuses on transforming the healthcare sector by increasing private sector participation, improving healthcare infrastructure, and enhancing public health. Key initiatives such as the National Transformation Program (NTP) aim to reduce the incidence of lifestyle-related diseases like diabetes by promoting preventive care and improving the accessibility of healthcare services.

Market Challenges

Limited Access to Specialist Care: Rural and underserved areas in Saudi Arabia face challenges in accessing specialized diabetes care. Urban centers are better equipped with medical facilities and specialists, but there remains a gap in healthcare access in more remote regions, leading to delayed diagnoses and inadequate disease management.

High Cost of Insulin and Devices: The cost of diabetes management remains a significant barrier for patients in Saudi Arabia. Insulin and advanced glucose-monitoring devices are expensive, particularly for those without adequate insurance coverage. This leads to underuse of necessary treatments, resulting in poor disease management and higher long-term healthcare costs.

KSA diabetes Market Future Outlook

Over the next five years, the KSA diabetes market is expected to witness sustained growth due to continuous government investment in healthcare infrastructure and increasing public awareness of diabetes management. The adoption of advanced technologies, such as continuous glucose monitoring systems and insulin pumps, will further accelerate growth. Additionally, the focus on early diagnosis, preventive care, and lifestyle management, in line with Vision 2030, will play a significant role in shaping the future of diabetes care in Saudi Arabia.

Future Market Opportunities

Adoption of Digital Health Solutions and Mobile Apps: The rise of digital health solutions presents a significant opportunity to improve diabetes management in Saudi Arabia. Mobile health apps and wearable devices that monitor glucose levels, track dietary intake, and encourage physical activity can support self-management for diabetes patients. These solutions can bridge the gap between patients and healthcare providers, especially in remote areas.

Investment in Telemedicine and Remote Patient Monitoring: Telemedicine offers an opportunity to extend the reach of diabetes care, especially in rural or underserved regions. The Saudi government and private healthcare providers have invested in telemedicine platforms to offer remote consultations, monitoring, and follow-up services for diabetic patients, allowing for more continuous and personalized care.
Please Note: It will take 5-7 business days to complete the report upon order confirmation